Pacira BioSciences Files Patent Lawsuits: What’s Next?

Company Overview and Key Products

Pacira BioSciences (NASDAQ: PCRX) is a specialty pharmaceutical company focused on non-opioid pain management. Its flagship product is EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic that accounted for about 80% of Pacira’s $675 million in 2023 revenues (^[1]) (^[1]). Pacira also markets ZILRETTA® (an extended-release corticosteroid injection for osteoarthritis knee pain) and iovera°® (a handheld cryoanalgesia device); ZILRETTA contributed ~$111 million in 2023 sales (around 16% of revenue) while iovera° is a smaller product (~3% of revenue) (^[1]). The company’s growth has recently leveled off – total revenues rose just 1% in 2023, with EXPAREL sales essentially flat year-over-year (^[1]). Pacira’s success remains highly dependent on EXPAREL’s commercial performance and its ability to expand use-cases (e.g. new nerve block indications) and drive uptake of ZILRETTA and iovera° (^[1]) (^[1]).

Patent Litigation Focus: Given Pacira’s heavy reliance on EXPAREL, protecting this franchise is critical. The company has aggressively built an intellectual property (IP) portfolio around EXPAREL, currently 21 U.S. patents listed in the FDA Orange Book covering the drug – grouped into two patent families expiring in January 2041 and July 2044 (^[2]). Over the past two years Pacira has engaged in multiple patent lawsuits to defend EXPAREL’s exclusivity. In December 2024, Pacira announced it was awarded a new U.S. patent (No. 12,156,940) on an enhanced manufacturing process for EXPAREL, expected to extend protection into July 2044 (^[3]). This “first in a new family of EXPAREL patents” underscores Pacira’s effort to fortify its IP and “expand EXPAREL’s patent life into 2044,” according to CEO Frank D. Lee (^[3]). With generics makers seeking to replicate EXPAREL’s formulation, Pacira’s patent strategy and litigation outcomes will be pivotal in shaping “what’s next” for the company.

Recent Patent Lawsuit Developments

In April 2025, Pacira reached a significant settlement with patent challengers Fresenius Kabi, Jiangsu Hengrui, and eVenus Pharmaceuticals regarding EXPAREL. Under the settlement, Pacira granted Fresenius a license to launch a generic version of EXPAREL no sooner than a confidential date in 2030 – and even then, only in volume-limited amounts, gradually scaling up to a cap in the high-30s% of U.S. market volume by 2035 (^[4]) (^[4]). Fresenius is further licensed for unlimited generic sales starting in 2039 (^[4]). In effect, this deal “protects the company’s commercial exclusivity…until a confidential date in 2030, with further provisions extending to 2039,” providing clarity that no full-scale generic EXPAREL can hit the U.S. market until 2039 (^[5]) (^[5]). Investors reacted very positively – Pacira’s stock price jumped about 15% on the settlement news, reflecting relief that a major generic threat was deferred (^[5]).

However, Pacira’s patent battles didn’t end there. In November 2025, the company disclosed it has filed new patent infringement lawsuits against The WhiteOak Group and Qilu Pharmaceutical, two other firms that filed Abbreviated New Drug Applications (ANDAs) to market generic EXPAREL (^[2]). By suing these applicants, Pacira triggered an automatic 30-month stay of FDA approval for the generics under the Hatch-Waxman Act (^[2]). In other words, the FDA cannot grant final approval to WhiteOak’s or Qilu’s generic versions until at least mid-2028 (30 months from the lawsuit filing) or unless Pacira loses in court sooner (^[2]). Pacira’s complaint seeks to enjoin (legally bar) any manufacture or sale of the proposed generics until its patents expire (^[2]). Given Pacira’s extensive patent estate (21 patents through 2041–2044), any would-be generic entrant faces a steep challenge – they would need to “overcome each of Pacira’s patents” via litigation or invalidation to launch a competing product (^[2]). Pacira has expressed full confidence in the strength of its EXPAREL IP and intends to “vigorously defend” its rights (^[2]). This latest legal offensive effectively buys Pacira time and preserves the status quo for the next few years. The open question is what comes next: whether these new cases will also end in a favorable settlement (as with Fresenius) or proceed to a court decision that could potentially alter EXPAREL’s exclusivity timeline. For now, Pacira has successfully pushed the immediate generic threat out to at least 2028, and likely much further given its patents extending into the 2040s (^[2]).

Dividend Policy and Shareholder Returns

Pacira does not pay a dividend and has never paid one since its inception (^[1]). Management has stated it intends to retain all earnings to reinvest in the business and fuel growth, rather than returning cash to shareholders (^[1]). In fact, Pacira explicitly notes “we do not expect to pay any cash dividends on our common stock in the foreseeable future”, citing the priority of funding development and expansion of its product portfolio (^[1]). As a result, Pacira’s dividend yield is 0%. This is typical for a mid-cap biotech/pharma company still focused on growth – available capital is directed toward R&D, strategic acquisitions (e.g. the 2021 Flexion Therapeutics takeover), and debt obligations rather than cash payouts. Investors in PCRX must look to share price appreciation for returns, as Pacira’s shareholder value strategy centers on expanding its non-opioid pain franchise (as seen with acquisitions and pipeline investments) rather than income distribution. Notably, Pacira also has no ongoing share repurchase program of significance, so total shareholder return is essentially tied to the stock’s performance. The lack of a dividend underscores management’s growth-orientation and the need to conserve cash for upcoming expenses – from clinical trials to potential contingent milestone payments related to the Flexion acquisition (up to $372 million by 2030 if certain ZILRETTA sales and pipeline approvals are achieved) (^[1]) (^[6]).

Financial Leverage, Debt Maturities, and Coverage

Pacira carries a moderate debt load, much of it stemming from low-interest convertible notes used to finance expansion. As of year-end 2023, the company had $522.4 million in total debt outstanding (^[1]). The debt structure includes a $115.2 million Term Loan A (bank term loan) maturing in March 2028 and, most significantly, $402.5 million of 0.750% Convertible Senior Notes due August 2025 (^[1]). A small legacy note assumed from Flexion ($8.6 million of 3.375% converts due May 2024) was essentially all repaid by early 2024 (^[1]). Pacira proactively refinanced a prior term loan in 2023 – replacing a higher-interest Term Loan B (which was set to mature 2026) with the new Term Loan A due 2028 – and used cash to pay down a portion of principal (^[1]) (^[1]). This refinancing helped cut annual interest expense nearly in half. In 2023, Pacira’s interest expense was $20.3 million, down 49% from ~$40 million in 2022 (^[1]) (^[1]). The company credited the drop to retiring the costlier Term Loan B and fully eliminating an older 2.375% convertible note that matured in 2022 (^[1]). The result is improved interest coverage – with 2023 adjusted EBITDA of $214 million and GAAP net income of $42 million (^[7]), Pacira had ample operating earnings to cover its $20 million interest burden. In fact, net interest (interest expense minus interest income) was under $9 million in 2023, given Pacira’s cash on hand generates interest income (^[1]).

Pacira’s balance sheet liquidity appears solid for now. At December 31, 2023, the company held $153.3 million in cash plus $125.3 million in short-term investments (total ~$278.6 million in liquid funds) (^[1]). Working capital stood at $412.6 million (^[1]). Management believes existing cash and ongoing cash flow from product sales will be sufficient to fund operations and meet all upcoming debt service and maturities over at least the next 12 months (^[1]). Notably, Pacira has expressed confidence that it can handle the August 2025 maturity of the $402.5 million convertible notes through internal resources (^[1]). However, this looming 2025 note is a key item to watch. The convertible carries a low 0.75% coupon and features an initial conversion price of ~$71.78 per share (^[1]). Pacira’s stock currently trades well below that level, meaning it is unlikely noteholders will voluntarily convert to equity. If the share price remains below the conversion threshold by 2025, Pacira will face a large cash outlay of $402.5 million to redeem the notes at maturity.

There are covenants tied to this maturity as well: under its credit agreement, Pacira must maintain at least $500 million in unrestricted cash (minus any prepayments of the 2025 notes) starting 91 days before the note’s due date (^[1]). This effectively forces Pacira to either refinance or accumulate additional cash by late spring 2025 to satisfy either the note repayment or the covenant buffer. Current cash on hand (~$279 million) is short of that requirement (^[1]), so management may choose to raise capital or use a portion of its $214 million+ in annual EBITDA and any excess cash flow in 2024–25 to build the necessary liquidity. The company’s stated plan is to fund the 2025 note and other obligations with operating cash, but refinancing or other financing actions remain possible if cash generation falls short. Encouragingly, Pacira’s leverage is not excessive – net debt is roughly $244 million (debt minus cash) which is around 1.1× 2023 adjusted EBITDA. This gives the company some flexibility to refinance on reasonable terms if needed. Still, investors will closely monitor Pacira’s strategy for the 2025 notes: whether it might negotiate conversions with bondholders, issue a new debt or equity deal, or utilize its cash reserves. Successfully navigating this maturity with minimal dilution or disruption will be important to Pacira’s financial health.

Valuation and Comparative Metrics

Pacira’s equity valuation reflects its stable EXPAREL franchise and long-term growth bets, but also the overhang of patent uncertainties. As of mid-2023, the stock traded around $40 per share, implying a market capitalization of roughly $1.8 billion (the value of non-affiliate shares alone was ~$1.3 billion at $40.07/share) (^[1]). At that price, Pacira’s enterprise value (EV) – market cap plus net debt – was approximately $2.1 billion. Relative to 2023 performance, this equates to about 10× EV/EBITDA on adjusted EBITDA of $214 million (^[7]). Price-to-earnings is less meaningful given GAAP net income was only $42 million (P/E in the 40s), depressed by substantial non-cash amortization and one-time charges. On a forward basis, analysts and the company’s guidance suggest only modest growth in the near term: Pacira’s 2024 revenue outlook is $680–$705 million (just 1–4% growth) (^[7]), with similar operating expense levels as 2023. This muted growth trajectory – EXPAREL sales are mature in many markets – means Pacira’s current valuation isn’t particularly cheap nor expensive for its niche. An EV/EBITDA around 10× is in line with many mid-cap pharmaceutical peers, especially considering Pacira’s high gross margins (~75% non-GAAP) (^[7]) and dependable cash flows from an established product. Investors appear to be valuing Pacira as a steady business with a long-lived cash cow (EXPAREL) balanced against the eventual erosion from generic competition down the road.

It’s worth noting how patent developments have influenced Pacira’s stock performance. The April 2025 patent litigation settlement was seen as a big win – as mentioned, shares popped ~15% on that news (^[5]). Pushing potential generic entry out to 2030/2039 significantly de-risked the valuation in investors’ eyes. Conversely, whenever generic threats have loomed, Pacira’s stock has felt pressure. For example, reports in mid-2024 of an FDA filing for a generic EXPAREL by a Chinese drugmaker (likely referring to Qilu) initially hurt sentiment (^[8]). Nonetheless, equity analysts have largely maintained a positive outlook. RBC Capital in July 2024 reaffirmed an “Outperform” rating on PCRX despite news of a generic challenge, reasoning that Pacira’s patent estate (with Orange Book protection into 2041) creates a formidable barrier to entry (^[9]). The RBC analyst noted their own legal analysis aligned with Pacira’s confidence in defending EXPAREL’s IP (^[9]). In essence, Wall Street recognizes that while generics will arrive eventually, Pacira has bought itself considerable time. The current valuation likely embeds the expectation that meaningful generic impact is a mid-2030s event, giving Pacira years to generate cash and develop new avenues of growth. Any changes to that timeline – for example, an unfavorable court ruling that enables an earlier generic launch – would be a downside risk to the stock’s valuation. On the upside, successful pipeline progress (e.g. Pacira’s gene therapy candidate PCRX-201 for osteoarthritis) or accretive acquisitions could drive future earnings higher than the market currently anticipates. At present, Pacira’s stock trades more on its defensive qualities (steady pain-treatment revenues, strong IP wall) than on high-growth excitement, as reflected in its moderate earnings multiple and analyst positioning.

Risks, Red Flags, and Challenges

Despite its strengths, Pacira faces several key risks and red flags that investors should monitor:

URGENT: Get “Trump\'s Secret Fund” — Learn How to Collect Royalty Checks

Limited report reveals the #1 American oil & gas royalty play that can start paying monthly — with just $50.

Mobile-friendly
Start w/ $50

Yes — Send My Report
Fast download • Instant access • Seats limited

– Heavy Reliance on One Product: EXPAREL makes up the majority of Pacira’s revenue (80% in 2023) (^[1]). This lack of diversification means the company’s fortunes are tied to a single product’s success. Any issues with EXPAREL – such as safety concerns, shifts in medical practice, or reimbursement changes – could severely impact Pacira. For instance, if hospitals or surgeons adopt alternative analgesics or techniques that reduce EXPAREL use (perhaps due to cost or new clinical data), Pacira would struggle to replace that lost revenue. Management acknowledges that “our success depends primarily on our ability to successfully commercialize EXPAREL and ZILRETTA” (^[1]), highlighting the concentration risk. So far, ZILRETTA and iovera° provide only incremental diversification. This high product concentration is a red flag, especially as EXPAREL approaches saturation in its core market of post-surgical pain management.

– Patent Litigation and Generic Threat: While Pacira has so far been effective in defending EXPAREL’s turf, the threat of generic competition is a constant overhang. Patent challenges by multiple players (Fresenius, Hengrui, eVenus, Qilu, etc.) indicate generics manufacturers are eager to enter the market. Pacira did suffer a setback in 2023 when a New Jersey court found one of its older EXPAREL patents invalid (the ’495 patent) (^[3]), though Pacira quickly pivoted by securing new patents and appealing decisions. The outcomes of ongoing and future lawsuits are uncertain – an adverse court ruling could open the door for a generic much sooner than 2039. Even the April 2025 settlement, while positive, allows some generic entry (limited volume) by early 2030 (^[5]) (^[5]). Competition could gradually chip away at Pacira’s share from 2030 onward if volume-limited generics enter. And with new litigants like Qilu and WhiteOak, there’s always a risk that one might fight to a judgment. If Pacira’s newer patents were proven invalid or not infringed, a generic might launch earlier than expected (e.g. in 2028–2029 after the 30-month stay). Intellectual property risk remains the top risk factor for Pacira – the company itself stresses that all patents eventually expire and that it may not be able to prevent competitors from challenging its IP (^[1]) (^[1]). Investors should be prepared for periodic legal twists and volatility around these events.

– Large 2025 Debt Maturity and Financing Needs: As discussed, Pacira must address the $402.5 million convertible notes due August 2025. If its cash generation or reserves fall short, Pacira might need to raise capital under pressure. That could mean new debt (at interest rates likely much higher than 0.75%) or issuing equity, either of which poses risks. Heavier debt at higher rates would squeeze future earnings with interest costs, while equity issuance could dilute existing shareholders. The company’s credit facilities impose restrictions as well – for example, covenants that require high cash balances pre-maturity (^[1]) and limit certain payments (^[1]). Breaching a covenant or scrambling for last-minute funds would be a red flag in terms of financial management. So far Pacira has responsibly managed its debt (even reducing total debt in 2023 by ~$167 million) (^[1]). But the 2025 deadline is looming; failure to smoothly handle this could negatively affect Pacira’s financial stability and investor confidence.

– Contingent Liabilities from Flexion Acquisition: Pacira’s 2021 acquisition of Flexion Therapeutics came with Contingent Value Rights (CVRs) that could obligate Pacira to pay up to $8.00 per Flexion share in cash if certain milestones are hit (^[6]) (^[6]). In aggregate this is up to ~$372 million by 2030 (^[1]). The milestones include ambitious ZILRETTA sales targets ($250M, $375M, $500M annual sales unlock payments of $1, $2, $3 per share respectively) and FDA approvals of two pipeline candidates (each worth $1 per share) (^[6]). While it would be a “high-class problem” (since hitting those milestones means ZILRETTA is a commercial success and pipeline products advanced), it nonetheless represents a potential cash outflow. If, say, ZILRETTA somehow achieved $500M in sales in a year, Pacira would owe over $130 million to former Flexion shareholders (approximately $3 × ~46 million shares) – eating into the very revenue windfall ZILRETTA provided. This risk isn’t immediate (ZILRETTA sales are ~$111M currently (^[1])), but investors should be aware that future success of acquired products could trigger big payouts, reducing the net benefit to Pacira. Pacira will need to plan for these possibilities when allocating capital in the late 2020s.

– Slow Growth and Execution Risks: Another concern is Pacira’s recent stall in revenue growth. EXPAREL’s growth has plateaued (only +0.2% in 2023 (^[1])), suggesting market penetration may be near its limit in core uses. Pacira’s growth strategy hinges on expanding indications (e.g. new nerve block approvals for EXPAREL), increasing penetration in ambulatory surgery centers, and international expansion – all of which come with execution challenges. Outside the U.S., adoption has been minimal so far (international sales are <1% of revenue (^[1])). Pacira’s pipeline is relatively small; aside from the recently acquired gene therapy PCRX-201 (formerly FX201) for osteoarthritis, there are few near-term product launches. If new growth drivers don’t materialize by the time EXPAREL does face generics, Pacira could see a decline in revenues. The company also underwent a leadership transition – long-time CEO Dave Stack stepped down and was succeeded by Frank D. Lee in early 2024 (^[7]) (^[7]). Any change at the top introduces uncertainty: the new CEO must maintain momentum and effectively manage the next phase (including integrating R&D initiatives and possibly pruning less fruitful projects). Operational issues, such as manufacturing scale-up (Pacira just got FDA approval for a new EXPAREL 200L manufacturing suite in Feb 2024 (^[7])) and supply chain management, also pose risks if not executed flawlessly (^[1]) (^[1]). In summary, Pacira faces the classic mid-sized pharma challenge of sustaining growth as its primary asset matures – all while warding off competitors and managing financial obligations.

– Regulatory and Market Risks: Pacira’s products, being alternatives to opioids, benefit from the medical community’s drive for non-opioid pain relief. However, they are not immune to regulatory and market pressures. For example, reimbursement policies could change – if government or insurers decide not to provide adequate payment for EXPAREL or ZILRETTA, hospitals might opt for cheaper pain solutions (^[1]) (^[1]). There is also competition from other pain therapies (e.g. generic bupivacaine injections, devices, or newer analgesic drugs). Any negative clinical findings or safety issues could hurt uptake (Pacira had in the past to address concerns about EXPAREL’s nerve block usage, etc.). Furthermore, the healthcare environment (like elective surgery volumes) can impact EXPAREL demand; we saw during COVID-19 that fewer surgeries led to lower EXPAREL sales (^[1]). These external factors are hard to predict but remain risks to Pacira’s operating performance.

In total, Pacira’s risk profile centers on defending its turf and extending its runway. The company’s own risk factor summary highlights many of the above issues, from dependency on key products to potential failure of pipeline R&D, legal liabilities, and substantial debt obligations (^[1]) (^[1]). Investors should keep an eye on indicators such as ongoing patent case developments, quarterly EXPAREL sales trends, progress on new product candidates, and any signals of financing moves as 2025 approaches.

Open Questions and Future Outlook

With the context of Pacira’s current situation, several open questions emerge about what’s next for the company:

– How Long Can EXPAREL Remain Unchallenged? – Pacira’s recent legal victories and new patents potentially secure EXPAREL’s U.S. exclusivity into the 2030s. Yet, the landscape can change if a generic challenger is willing to take a patent fight all the way. Will Pacira continue to settle with challengers (as with Fresenius) to carefully manage if and when generics enter, or will a court eventually decide an outcome? The 30-month stay until mid-2028 (from the WhiteOak/Qilu lawsuits) buys time (^[2]), but investors will be watching for any trial schedules or settlement talks. A key question is whether Pacira’s patents (especially the new 2041/2044 expiries) will hold up under scrutiny. So far, the company expresses “full confidence” in its patent portfolio (^[2]) and even third-party analysis (e.g., RBC’s legal checks) support the view that generics face high hurdles (^[9]). If Pacira can maintain a patent wall through 2039 or beyond, EXPAREL could enjoy essentially a full lifecycle without major generic erosion – a scenario that would significantly boost the long-term outlook. Conversely, any crack in the IP armor is a game-changer. This open question will likely persist until at least the late 2020s, unless further settlements extend clarity.

– How Will Pacira Handle the 2025 Convertible Notes? – The clock is ticking toward August 2025, when $402.5 million comes due (^[1]) (^[1]). Pacira’s management insists it can cover this with existing cash and cash to be generated (^[1]), but the market will want to see concrete plans. Will Pacira refinance by issuing a new bond or term loan (potentially at a much higher interest rate)? Could it negotiate a partial conversion or extension with noteholders, especially if the stock price improves? Or might Pacira even consider an equity raise to retire the debt? The outcome has implications for shareholders – a refinancing could increase interest expense (pressuring earnings), while an equity issuance could dilute ownership. There’s also a strategic angle: paying off the converts would remove the restrictive cash covenant (^[1]), possibly freeing Pacira to use cash more flexibly. How the company navigates this in 2024–25 will signal its financial strategy discipline. This question should be answered within the next few quarters, as 2025 approaches.

– Can New Products Drive Meaningful Growth? – With EXPAREL’s growth slowing, Pacira’s next leg of growth could come from pipeline developments or acquisitions. The company’s “5×30” strategy mentioned by management suggests an ambition to have five significant revenue contributors by 2030 (^[4]). Currently, it has three (EXPAREL, ZILRETTA, iovera°). One pipeline hopeful is PCRX-201, a gene therapy (enasidenovec) for osteoarthritis pain in development (^[2]). There’s also FX301 (now PCRX-301, a nerve block anesthetic in early stages) whose approval by 2030 could trigger a Flexion CVR payout (^[6]). Open questions include: Will PCRX-201 show compelling clinical results and get FDA approval? As a gene therapy for OA, it’s an innovative approach but unproven – success could open a huge market and diversify Pacira beyond perioperative pain. Pacira’s R&D spend (~$70–$80M guided for 2024 (^[7])) is largely aimed at such programs. Another question: Can ZILRETTA be expanded to other joints or uses to boost sales? At $100+ million annually, ZILRETTA is valuable but far from reaching the CVR sales milestones (which top out at $500M) (^[6]). Perhaps label expansions or new clinical data might accelerate its adoption in osteoarthritis treatment. Additionally, international expansion for EXPAREL remains an opportunity – will Pacira secure approvals and commercial traction in key ex-U.S. markets (Europe, Asia)? To date, non-U.S. sales are negligible (^[1]), but Pacira has partners abroad and a newly approved manufacturing suite that could support global supply (^[7]). Progress on these fronts will determine if Pacira’s revenue can re-accelerate or if it will remain flat until it eventually dips post-Exparel exclusivity.

– Will Pacira Pursue Further M&A? – The company has grown in part by acquisition (MyoScience for iovera°, Flexion for Zilretta). With strong cash flows and a still-manageable debt profile, Pacira might seek bolt-on acquisitions to broaden its pain management portfolio. An open question is whether management will attempt another deal in the coming years to add a fourth or fifth product line. The right acquisition could reignite growth and reduce dependence on EXPAREL. However, any M&A would need to be carefully weighed against Pacira’s leverage and the imperative of preserving cash for 2025. Investors will be attentive to any signals (comments on earnings calls, etc.) about M&A appetite.

– How Will the Market Evolve for Non-Opioid Pain Therapies? – On a higher level, Pacira’s mission aligns with healthcare trends to reduce opioid use. This is a tailwind, but also invites competition. There are other non-opioid analgesic technologies being developed (for example, nerve block pumps, long-acting numbing agents, etc.). A critical question: Can Pacira maintain its leadership and differentiate EXPAREL against both existing and emerging competitors? The company already faces some competition (e.g., Heron Therapeutics launched a post-surgical analgesic called Zynrelef, though its uptake has been limited). If a new breakthrough pain therapy arrives, it could potentially disrupt EXPAREL’s position. Pacira will likely continue to emphasize clinical data and real-world outcomes to defend its products’ value proposition in the marketplace. The ongoing need for effective, opioid-sparing pain relief suggests demand will remain, but Pacira must stay innovative to hold its edge.

Looking ahead, Pacira’s base case outlook appears stable: incremental growth in the near term, robust profit margins, and substantial free cash flow generation as long as EXPAREL remains essentially exclusive. The company projects maintaining mid-70s% gross margins and healthy adjusted EBITDA margins, which should enable debt reduction and possibly shareholder-friendly moves once the 2025 note is dealt with. Pacira’s long-term trajectory, however, hinges on the resolution of the above open questions. If it can postpone meaningful generic competition to late 2030s, successfully launch new therapies, and perhaps leverage its expertise in pain management into new opportunities, Pacira could extend its run as a leading non-opioid pain company well into the next decade. On the other hand, any missteps – a legal loss, a financing crunch, or a failed pipeline bet – could significantly alter its course. In summary, Pacira BioSciences is at a strategic inflection: armed with patent wins and a strong balance sheet, it has bought itself time to write the next chapter beyond EXPAREL. The coming years will reveal how effectively the company uses that time to diversify, innovate, and prepare for the eventual post-patent era.

Sources:

1. Pacira BioSciences 2023 Annual Report (Form 10-K) (^[1]) (^[1]) (^[1]) (^[1]) 2. Pacira Q4 and Full-Year 2023 Earnings Release (^[7]) (^[7]) 3. Pacira Investor Relations – Patent Litigation Settlement Press Release (April 7, 2025) (^[4]) (^[4]) 4. Pacira Investor Relations – Patent Lawsuit Filing Press Release (Nov 26, 2025) (^[2]) (^[2]) 5. GlobeNewswire/Investing.com – “Pacira BioSciences stock surges on patent litigation settlement” (^[5]) (^[5]) 6. Investing.com – “Pacira stock holds strong with Outperform rating despite FDA nod to generic” (^[9]) 7. Pacira Investor Relations – “Pacira Awarded New U.S. Patent Covering EXPAREL Composition” Press Release (Dec 3, 2024) (^[3]) 8. Pacira Investor Relations – Flexion Acquisition and CVR Details (Oct 11, 2021) (^[6])

Sources

1. https://sec.gov/Archives/edgar/data/1396814/000139681424000030/pcrx-20231231.htm
2. https://globenewswire.com/news-release/2025/11/26/3195373/0/en/Pacira-BioSciences-Files-EXPAREL-Patent-Infringement-Lawsuits-Against-The-WhiteOak-Group-and-Qilu-Pharmaceutical.html
3. https://investor.pacira.com/news-releases/news-release-details/pacira-awarded-new-us-patent-covering-exparel-composition
4. https://biospace.com/press-releases/pacira-biosciences-announces-settlement-of-u-s-patent-litigation-for-exparel
5. https://za.investing.com/news/stock-market-news/pacira-biosciences-stock-surges-on-patent-litigation-settlement-93CH-3646164
6. https://investor.pacira.com/news-releases/news-release-details/pacira-biosciences-acquire-flexion-therapeutics-further
7. https://investor.pacira.com/news-releases/news-release-details/pacira-biosciences-reports-fourth-quarter-and-full-year-2023
8. https://ainvest.com/news/pacira-biosciences-shares-plummet-fda-filing-generic-exparel-2510/
9. https://investing.com/news/company-news/pacira-stock-holds-strong-with-outperform-rating-despite-fda-nod-to-generic-93CH-3505936

For informational purposes only; not investment advice.